Trending Stocks Analysis Report: Apollo Commercial Real Estate Finance, Inc. (ARI), Repros Therapeutics Inc. (RPRX)

united airlines settlement

Apollo Commercial Real Estate Finance, Inc. (ARI)

The company announced its last quarter financial performance results on 11/01/2017. Apollo Commercial Real Estate Finance, Inc. (ARI) belongs to Finance sector that declined -0.22% in value when last trading session closed at $18.28. The company has a market capitalization of $1.98 Billion. The company’s stock has a Return on Assets (ROA) of 4.5 percent, a Return on Equity (ROE) of 8.3 percent and Return on Investment (ROI) of 5.8 percent. The company reached its 52-Week high of $19.92 on 04/27/17 and 52-Week low of $16.84 on 01/09/17.

Earnings per share (ttm) for Apollo Commercial Real Estate Finance, Inc. (ARI) according to Finviz Data is $1.79.

The growth estimate for Apollo Commercial Real Estate Finance, Inc. (ARI) for the current quarter is -12.2 percent. The projected growth estimate for the next quarter is 24.4 percent. The company’s stock has grown by 7.68 percent in the past 5 years. For the next 5 years, the company is expected to grow by 0.3 percent.

The 5 analysts offering 12-month price forecasts for Apollo Commercial Real Estate Finance Inc have a median target of 18.00, with a high estimate of 19.00 and a low estimate of 17.00. The median estimate represents a -1.53% decrease from the last price of 18.28.

Financial History:

Following Earnings result, share price were DOWN 21 times out of last 32 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 8% percent of times. It has met expectations  0 times and missed earnings  1 times.

The consensus recommendation for Apollo Commercial Real Estate Finance, Inc. (ARI) is 3. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 3. In comparison, the consensus recommendation 60 days ago was at 3, and 90 days ago was at 3 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Apollo Commercial Real Estate Finance, Inc. to have earnings per share of $0.43.

Revenue is expected to range from 67.7 Million to 74.4 Million with an average of 4000.

Company Profile:

Apollo Commercial Real Estate Finance, Inc. is focused on investing in, acquiring and managing senior performing commercial real estate mortgage loans, commercial mortgage-backed securities, commercial real estate corporate debt and loans, and other real estate debt investments. The Company is a commercial real estate finance company that is managed and advised by ACREFI Management, LLC, a indirect subsidiary of Apollo Global Management, LLC.

Repros Therapeutics Inc. (RPRX):

Repros Therapeutics Inc. (RPRX) belongs to Medical sector closed its last session with a declined of -0.15 percent and closed its previous trading session at $0.66. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-0.5. The company has the Market capitalization of $25.62 Million. The company’s stock has a Return on Assets (ROA) of -230.5 percent, a Return on Equity (ROE) of -895.2 percent and Return on Investment (ROI) of 0 percent. The company reached its 52-Week high of $1.55 on 01/30/17 and 52-Week low of $0.26 on 08/22/17.

The 1 analysts offering 12-month price forecasts for Repros Therapeutics Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +654.15% increase from the last price of 0.66.

Financial History:

Following Earnings result, share price were DOWN 16 times out of last 32 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 16% percent of times. It has met expectations  0 times and missed earnings  0 times.

Future Expectations:

When the current quarter ends, Wall Street expects Repros Therapeutics Inc. to have earnings per share of $-0.32.

Company Profile:

Zonagen Inc. is a biopharmaceutical company engaged in the development of products for the human reproductive system, including sexual dysfunction, vaccine adjuvants, products for fertility and female health as well as urological applications, specifically prostate cancer.  Zonagen’s products to treat sexual dysfunction all incorporate phentolamine mesylate, an alpha-adrenergic blocker, as the active agent.  Zonagen’s lead product, VASOMAX(R), is a rapidly disintegrating oral formulation of phentolamine for the treatment of male erectile dysfunction.